Findings show a significant decrease in VEGF-A levels in the first week after ROP treatment (ratio of means [95% confidence interval] 0.34 [0.25–0.45], I2 = 97%, 17 publications). The gene discussed is VEGFA; the disease is retinopathy of prematurity.